Építés alatt – nem éles oldal
Belépés

NCT07408869Visszavonva1. fázis

A Phase 1 Study of Cizutamig in IgE Mediated Diseases

A Phase 1b, Open-Label Study Evaluating the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Cizutamig in IgE Mediated Diseases

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. júl. 22.

Megadott ok: Sponsor decision

Rövid összefoglaló (regiszter, angolul)

The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.

Állapot (regiszter)
Visszavonva
Fázis (regiszter)
1. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
0 (tényleges)
Első benyújtás
2025. dec. 23.
Kezdés
2026. ápr.
Elsődleges befejezés
2026. dec.
Fő szponzor
Candid Therapeutics
NCT-szám
NCT07408869

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Current use of any allergen immunotherapy.
  • Receipt of or inability to discontinue any excluded therapies
  • Major surgery requiring the use of general anesthesia within 12 weeks prior to Screening or planned or expected major surgery during the study period
  • Blood donation or significant blood loss within 30 days prior to screening

Más betegség

  • Elevated IgE levels for reasons other than the IgE mediated diseases
  • Planned ingestion of food items to which they are allergic for the duration of the study (for food allergy patients)
  • Active infection
  • Serious mental illness, drug or alcohol abuse, dementia, or other condition that impair ability to sign ICF
  • History of primary immunodeficiency
  • History of CNS disease
  • History of poorly controlled diabetes, chronic kidney disease, chronic pulmonary disease, uncontrolled cardiovascular disease, history of malignancy within 5 years
  • History of severe allergic or anaphylactic reactions to mAb therapy (or recombination antibody-related fusion proteins) or any constituents of study drug
  • A history of severe allergic or anaphylactic reactions related to the underlying IgE mediated disease

Laborértékek

  • Inadequate clinical laboratory parameters at Screening

Egyéb

  • Individuals whose allergen exposures in their home and/or work environments may be expected to change significantly during the trial period
  • Individuals who will decline blood products
  • Individuals who are hypersensitive to intravenous immunoglobulin (IVIg)
  • Individuals considered to be part of a vulnerable population (eg, incarceration)
  • Individuals that in the opinion of the Investigator, are not suitable for participation in the trial
  • Inability to comply with protocol-mandated requirements

Kiket keres a vizsgálat

  • Patient meets at least one of the following:
    • History of documented (skin prick test, in vitro testing, or food challenge), ongoing, IgE-mediated allergy to food (eg, peanut, hazelnut, walnut, cashew, milk, egg/egg white, soy, wheat, sesame, cod, salmon, tuna, lobster, crab and/or shrimp) with Screening total IgE ≥ 400 IU/mL
    • Diagnosis of chronic rhinosinusitis with Screening total IgE > ULN
    • Diagnosis of allergic rhinitis with Screening total IgE > ULN
    • Diagnosis of asthma and classified as well controlled per 2024 Global Initiative for Asthma guidelines with Screening total IgE > ULN
    • Diagnosis of chronic spontaneous urticaria with symptoms (eg, wheals or angioedema) for at least 6 weeks any time prior to screening and Screening total IgE > ULN
    • Diagnosis of atopic dermatitis that has been present for at least 6 months before the screening visit and with Screening total IgE > ULN
  • Agree to the use of highly effective contraception

Életkor a regiszterben: 18 év – 65 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Nucleus NetworkMelbourneAusztráliaIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.